Catalyst

Slingshot members are tracking this event:

Tesaro (TSRO) Plans to Report Phase 2 AVANOVA Data in 2H 2018 Evaluating Niraparib + Bevacizumab in Ovarian Cancer

Source Link:
http://ir.tesarobio.com/news-releases/news-release-details/tesaro-announces-fourth-quarter-and-full-year-2017-operating

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
TSRO
100%
SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details Update on Feb 27 2018: Initially expected 2H 2017, it is now due for 2H 2018.
http://files.shareho...
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Jun 04, 2019
Occurred Source:
https://www.onclive.com/conference-coverage/asco-2019/niraparibbevacizumab-combo-active-in-recurrent-ovarian-cancer
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 2, Avanova, Niraparib, Bevacizumab, Ovarian Cancer
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.